On March 31, 2014, Cytomedix, Inc. (CMXI) reported financial results for the fourth quarter and full year ended December 31, 2013. Total revenues in the quarter were $3.5 million, an increase of 65% over the fourth quarter 2012. Revenues were driven by $3.0 million in product sales, $0.3 million in royalties, and $0.2 million in licensing fees and other income. Product sales consisted of $2.8 million in recorded pass-through sales of Angel to Arthrex, Inc. and $0.2 million in sales of AutoloGel.
Angel sales increased 48% from the fourth quarter 2012. We remind investors that Cytomedix controls the manufacturing of the Angel device and thus records the associated revenue and expenses from the product on its income statement. Sales of
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|